Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms

Samee Zane Alheraki; Daniel R. Almquist; Jason S. Starr; Thorvardur R. Halfdanarson; Mohamad Bassam Sonbol

Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms

Samee Zane Alheraki, Daniel R. Almquist, Jason S. Starr, Thorvardur R. Halfdanarson, Mohamad Bassam Sonbol

Medical Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) neuroendocrine malignancies that comprise both rapidly proliferating, well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinomas (NEC). The phenotypic differences between NET G3 and NEC stem from differences in their underlying genomic alterations. As a result of these differences, NET G3 is molecularly, radiologically, and prognostically distinct from NEC. The optimal management of NET G3 and NEC is currently being refined through clinical trials that focus on NET G3 and NEC as separate entities. This review aims to summarize the current understanding of NEN G3 by distinguishing between NET G3 and NEC and describing the clinical implications associated with each.

Original language	English (US)
Pages (from-to)	16-26
Number of pages	11
Journal	Clinical Advances in Hematology and Oncology
Volume	21
Issue number	1
State	Published - Jan 2023

Keywords

High-grade
NEC
NET G3
Neoplasms
Neuroendocrine
Peptide receptor radionucleotide therapy

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{d23dc9d468314e64b7923d468f1cc50f,

title = "Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms",

abstract = "Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) neuroendocrine malignancies that comprise both rapidly proliferating, well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinomas (NEC). The phenotypic differences between NET G3 and NEC stem from differences in their underlying genomic alterations. As a result of these differences, NET G3 is molecularly, radiologically, and prognostically distinct from NEC. The optimal management of NET G3 and NEC is currently being refined through clinical trials that focus on NET G3 and NEC as separate entities. This review aims to summarize the current understanding of NEN G3 by distinguishing between NET G3 and NEC and describing the clinical implications associated with each.",

keywords = "High-grade, NEC, NET G3, Neoplasms, Neuroendocrine, Peptide receptor radionucleotide therapy",

author = "Alheraki, {Samee Zane} and Almquist, {Daniel R.} and Starr, {Jason S.} and Halfdanarson, {Thorvardur R.} and Sonbol, {Mohamad Bassam}",

year = "2023",

month = jan,

language = "English (US)",

volume = "21",

pages = "16--26",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "1",

}

TY - JOUR

T1 - Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms

AU - Alheraki, Samee Zane

AU - Almquist, Daniel R.

AU - Starr, Jason S.

AU - Halfdanarson, Thorvardur R.

AU - Sonbol, Mohamad Bassam

PY - 2023/1

Y1 - 2023/1

N2 - Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) neuroendocrine malignancies that comprise both rapidly proliferating, well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinomas (NEC). The phenotypic differences between NET G3 and NEC stem from differences in their underlying genomic alterations. As a result of these differences, NET G3 is molecularly, radiologically, and prognostically distinct from NEC. The optimal management of NET G3 and NEC is currently being refined through clinical trials that focus on NET G3 and NEC as separate entities. This review aims to summarize the current understanding of NEN G3 by distinguishing between NET G3 and NEC and describing the clinical implications associated with each.

AB - Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) neuroendocrine malignancies that comprise both rapidly proliferating, well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinomas (NEC). The phenotypic differences between NET G3 and NEC stem from differences in their underlying genomic alterations. As a result of these differences, NET G3 is molecularly, radiologically, and prognostically distinct from NEC. The optimal management of NET G3 and NEC is currently being refined through clinical trials that focus on NET G3 and NEC as separate entities. This review aims to summarize the current understanding of NEN G3 by distinguishing between NET G3 and NEC and describing the clinical implications associated with each.

KW - High-grade

KW - NEC

KW - NET G3

KW - Neoplasms

KW - Neuroendocrine

KW - Peptide receptor radionucleotide therapy

UR - http://www.scopus.com/inward/record.url?scp=85146364249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146364249&partnerID=8YFLogxK

M3 - Article

C2 - 36638352

AN - SCOPUS:85146364249

SN - 1543-0790

VL - 21

SP - 16

EP - 26

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 1

ER -

Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this